Total Utang marang Modal Kairos Pharma Ltd (KAPA)
Kairos Pharma Ltd (KAPA) faces uncertainty regarding new drug test results and the search for partners, yet relies on a dedicated staff of scientists motivated by stock options. This chart of the total debt-to-equity ratio captures a value of 0.00. The business focuses on developing a targeted immune response system, which could radically shift therapy standards for lung and prostate tumors.
%20-%20Total%20Utang%20marang%20Modal&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261031&filename=GURU_Markets_-_KAPA_-_Kairos-Pharma-Ltd_-_Total-Debt-to-Capital "Utang marang Ekuitas Kairos Pharma Ltd (KAPA): kanggo periode 17.09.2024 - 31.10.2026 | 👁️GURU.Markets👁️")
Rincian metrik lan analitis perusahaan Kairos Pharma (KAPA)
- rega saham lan konsensus proyeksi valuasi:
- rincian kapitalisasi pasar:
- indikator kapitalisasi buku:
- rincian utang lan likuiditas:
Total Utang marang Modal Kairos Pharma Ltd|KAPA - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Kairos Pharma Limited|KAPA - Kewajiban utang agregat|Utang marang nilai buku Kairos Pharma|KAPA - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Kairos Pharma|Indikator likuiditas cepet kairospharma.com
- data bathi resik lan rasio valuasi:
Pambiji fundamental perusahaan:Kairos Pharma Ltd
The implementation of AI in molecular design and the automation of drug synthesis at Kairos Pharma Ltd (KAPA) optimize drug development costs. The ratio of total liabilities to equity determines the degree of financial leverage, allowing an investor to assess the company's dependence on borrowed capital through changes in the proportion of total debt to equity.
Analisis pesaing Kairos Pharma Ltd
ONC (BeiGene) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas Halozyme Therapeutics, Inc. (HALO)|Total Utang marang Modal RVMD|Total Utang marang Modal Ascentage Pharma Corp (AAPG)|Utang marang Ekuitas CG Oncology, Inc. CGON|URGN: Rasio Utang marang Ekuitas|Bicara Therapeutics - Total Utang marang Modal|Personalis Inc (PSNL) - Rasio Total Utang marang Ekuitas|ERAS: Total Utang marang Modal|Utang marang Modal Delcath Corp (DCTH)|Utang marang Ekuitas Y-mAbs Therapeutics|AURA: Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas CADL (Candel Therapeutics)|ARAY (Accuray Inc) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal SLS (SELLAS Life Sciences Group)|ACTU - Rasio Total Utang marang Ekuitas|CTOR: Rasio Total Utang marang Ekuitas|HURA - Total Utang marang Modal|Protara Therapeutics, Inc. (TARA) - Utang marang Ekuitas|Fate Therapeutics Inc - Rasio Kabeh Utang marang Dana Pribadi|WHWK (Aadi Bioscience, Inc.) - Total Utang marang Modal|Utang marang Modal TScan TCRX|Utang marang Ekuitas Champions Oncology (CSBR)|Total Utang marang Modal xbiotech.com (XBIT)|Total Utang marang Modal CVM (CEL-SCI)|Total Utang marang Modal OS Therapies Inc. OSTX|Radiopharm Theranostics Limited - Total Utang marang Modal|Koefisien Total Utang marang Modal Artiva Biotherapeutics, Inc. ARTV|adlainortye.com (ANL) - Utang marang Ekuitas|verupharma.com - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Tempest Therapeutics, Inc.|Utang marang Modal Xilio XLO|Utang marang Ekuitas Renovaro Inc. (RENB)|Koefisien Total Utang marang Modal muraloncology.com|OnKure Therapeutics - Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi GDTC|CRIS - Utang marang Ekuitas|Utang Agregat marang Ekuitas APLM|THAR: Total Utang marang Modal|Advanced Biomed - Rasio Kabeh Utang marang Dana Pribadi|GNPX (Genprex, Inc.) - Total Utang marang Modal|Total Utang marang Modal Calidi Bio|Utang marang Ekuitas Sunshine Biopharma, Inc. (SBFM)|XBIO (xeneticbio.com) - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Salarius SLRX|PPBT - Rasio Total Utang marang Ekuitas|AON - Total Utang marang Modal|BGNE - Total Utang marang Modal|CKPT (Checkpoint Therapeutics, Inc.) - Rasio Total Utang marang Ekuitas|elevationoncology.com - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas iCAD Inc.|Utang marang Ekuitas IKNA|Rasio Total Utang marang Ekuitas NTBL (Notable Labs, Ltd.)|Utang Agregat marang Modal VIRX|Total Utang marang Modal MOR (MorphoSys)|NAYA: Rasio Utang marang Ekuitas|AAPGV - Utang marang Ekuitas